March 27, 2020 –  At Alector, we are proactively monitoring and assessing the current COVID-19 global pandemic, which has affected countless individuals around the world. As the situation evolves, our focus has been on developing and executing a comprehensive business continuity plan, with the safety and well-being of our employees, patients, and partners being our highest priority. 

We recognize that we are operating in an environment of uncertainty. Our entire organization is committed to advancing our mission of making dementia and neurodegeneration illnesses of the past. As the COVID-19 situation develops, we will continue to keep you updated.

Business Operations

Our focus is on executing a comprehensive business continuity plan, with the safety and well-being of our employees, patients and partners being our highest priority.

We are actively complying with the California state orders and follow guidance provided by WHO, CDC, and other health organizations. We are requiring any on-site employees to comply with “social distancing” guidance and enhanced safety and cleaning protocols, to support the flattening of the curve of COVID-19 cases.  

At this time we have not issued any changes to clinical timelines, but we will continue to monitor this. Should an impact from COVID-19 cause a material change to our previous guidance, we will communicate these changes to you via our website and our other communication channels. 

Should you have any questions or suggestions in regards to the COVID-19 pandemic, please contact us at ir@alector.com.

Our Employees and Community

    • We currently have transitioned into a partially virtual work environment, and have launched multiple employee-engagement programs aimed at enabling continued productivity on and off site.
    • We have suspended all international and domestic business travel until further notice.

Clinical Operations

    • We are in close communication with our clinical trial sites and external vendors to proactively tackle and minimize any potential disruptions. 
    • If you have any questions or concerns, please consult with the physicians at your clinical trial site.

Forward Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the ability and timing for the closing of the public offering of common stock. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed offering, and other risks and uncertainties related to the offering, Alector and its business as set forth in Alector’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2020. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.